Method if treating hepatic encephalopathy un cases of cirrhosis

FIELD: internal diseases.

SUBSTANCE: patient is administered diet including 0.3-0.5 g/kg/day animal for 10 days followed by increase to dose 0.8-1 g/kg/day during 1 month, after which 5% glucose solution is administered intravenously in dose 400-500 ml for 1 weak, lactulose in dose 60-90 ml divided into 2-3 intakes for 4 weeks, and probiotics over a 2-weak period 30 min before meal time. Simultaneously, L-ornithine-L-aspartate is given during 10 days in dose 30-40 g a day divided into 2-3 intakes followed by dose 5-7 g thrice a day during 10 days.

EFFECT: achieved involution of neurological and psychical manifestations of encephalopathy, reduced hepatic coma development incidence, and increased protein tolerance in patients.

4 cl, 3 ex

 

The invention relates to medicine and can be used as a method of correction of the state in hepatic encephalopathy.

There is a method of treatment of hepatic encephalopathy by application of neuroprotective drugs, taken as the analogue of [1].

There is a method of treatment of encephalopathy by the appointment of Cerebrolysin, methionine and glutamic acid [2], adopted for the prototype.

However, the prototype does not allow you to adjust the condition of patients with hepatic encephalopathy, occurring against the background of cirrhosis of the liver.

The aim of the invention is to increase the efficiency correction encephalopathy in patients with cirrhosis of the liver.

The technical result is achieved by the fact that the patient is prescribed a diet with animal protein 0.3-0.5 g/kg/day for 10 days, followed by its increase up to 0.8-1 g/kg/day for 1 month, spend intravenous 5% glucose solution at a dose of 400-500 ml in 1 week, receiving lactulose in doses of 60-90 ml, divided into 2-3 doses for 4 weeks, taking probiotics - 30 minutes before meals for 2 weeks; then take L-ornithine-L-aspartate in for 10 days at a dose of 30-40 mg/day, divided into 2-3 doses, followed by a reception at a dose of 5-7 g 3 times daily for 10 days;

the technical result is also achieved by the fact that as a probiotic use probfor 10 doses 3 times in the Yan;

the technical result is also achieved by the fact that as a probiotic use Bifidumbacterin Forte 10 doses 3 times a day;

the technical result is also achieved by the fact that as a probiotic use Bifiform 2 capsules 2 times a day.

The method is as follows.

The patient at admission celebrate the sleep disorder with disturbance of consciousness, drowsiness, lethargy, apathy, short answer, flapping tremor, sometimes the patient responds only to intense stimuli. Personality changes include the childishness, irritability, loss of interest in family, sometimes it's sociable, fewer social contacts. Often there are disorders associated with impaired optical-spatial activities. They are identified in the form of constructive apraxia, reflected in the inability of the patient to copy a simple pattern of cubes and matches, there has been a violation writing letters, handwriting. Criticism patient is saved, it becomes slow, monotonous. History is often possible gastrointestinal bleeding on the background of cirrhosis of the liver.

Determine the level of ammonia in the blood serum and the test is carried out the communication test numbers before and after treatment. The patient is prescribed a diet with animal protein 0.3-0.5 g/kg/day for 10 days and then increase to 0.8-1G/kg/day for 1 month, spend intravenous 5% glucose solution at a dose of 400-500 ml in 1 week, receiving lactulose in doses of 60-90 ml, divided into 2-3 doses for 4 weeks, taking probiotics - 30 minutes before meals for 2 weeks; then take L-ornithine-L-aspartate for 10 days at a dose of 30-40 mg/day, divided into 2-3 doses, followed by a reception at a dose of 5-7 g 3 times daily for 10 days; prescribe probiotics (probfor 10 doses 3 times a day or Bifidumbacterin Forte 10 doses 3 times a day or Bifiform 2 capsules 2 times a day) for 30 min before meals for 2 weeks.

Before treatment, the ammonia level is 80-90 mmol/l and the test connection numbers 90 and more. After 2.5-3 weeks from the start of treatment, the ammonia level is reduced to 65-70 mmol/l, and the test connection number is reduced to 70 and less. The results assess the patient's condition as satisfactory and consider treatment of hepatic encephalopathy in liver cirrhosis successful.

The method further illustrated by examples.

Example 1

Sick As in, 49 years old, was admitted with a diagnosis of viral cirrhosis of the liver, asthma, portal hypertension stage II, hepatic encephalopathy grade II ascites. Complain of sleep disturbance, daytime sleepiness, insomnia at night, marked lethargy, apathy, flapping tremor. The patient is somewhat irritable, family is not interested in. In Ana is Nese marked two episodes of bleeding from varicose veins of the esophagus. Determine the level of ammonia in the blood serum and the test is carried out the communication test numbers before treatment: the ammonia level is 80 mmol/l and the test connection numbers 120 C.

The patient is prescribed a diet with animal protein 0.5 g/kg/day for 10 days and then increase to 1 g/kg/day for 1 month, spend intravenous 5% glucose solution at a dose of 400 ml in 1 week, taking the lactulose dose of 60 ml, divided into 2 doses, for 4 weeks, taking probiotics - 30 minutes before meals for 2 weeks; then take L-ornithine-L-aspartate for 10 days at a dose of 30 g/day, divided into 2 doses, followed by a reception in a dose of 5 g 3 times daily for 10 days; prescribe probiotics (probfor 10 doses 3 times a day or Bifidumbacterin Forte 10 doses 3 times a day or Bifiform 2 capsules 2 times a day) for 30 min before meals for 2 weeks.

After 2.5 weeks of starting treatment, the ammonia level is reduced to 70 mmol/l, and the test connection number is reduced to 68 C.

The results assess the patient's condition as satisfactory and consider treatment of hepatic encephalopathy in liver cirrhosis successful.

The patient was discharged in satisfactory condition.

Subsequent follow-up observation for 6 months showed no progression of the disease

Example 2

The patient With Kaya,55, there is diagnosed with viral cirrhosis of the liver, subcompensated, portal hypertension stage II. Complications: hepatic encephalopathy stage III, ascites. Was admitted with complaints of sleep disturbances, weakness, memory impairment. Objective examination noted the brevity of answers, flapping tremor. The identity of the patient changed: irritability, social contact difficult, isolated disorders arise on a background of clear consciousness and involve a violation of optical-spatial activity in the form of constructive apraxia, reflected in the inability of the patient to copy a simple pattern of cubes and matches.

Determine the level of ammonia in the blood serum and the test is carried out the communication test numbers before treatment.

The patient is prescribed a diet with animal protein 0.4 g/kg/day for 10 days and then increase to 0.9 g/kg/day for 1 month, spend intravenous 5% glucose solution at a dose of 450 ml in 1 week, receiving lactulose dose of 80 ml, divided into 2 doses, for 4 weeks, taking probiotics - 30 minutes before meals for 2 weeks; then take L-ornithine-L-aspartate for 10 days at a dose of 35 g/day, divided into 3 doses, followed by a reception in a dose of 6 g 3 times daily for 10 days; prescribe probiotics (probfor 10 doses 3 times a day or BIFI is wmbattery Forte 10 doses 3 times a day or Bifiform 2 capsules 2 times daily) - 30 minutes before meals for 2 weeks.

Before treatment, the ammonia level is 90 mmol/l and the test connection numbers 125 C. After 3 weeks from the start of treatment, the ammonia level is reduced to 65 mmol/l, and the test connection number is reduced to 70. The results assess the patient's condition as satisfactory and consider treatment of hepatic encephalopathy in liver cirrhosis successful.

The patient improved psycho-emotional state, decreased irritability, ill gladly come into contact. Tests copying patterns succeeds.

The patient was discharged in a state of clinical and laboratory remission.

Example 3

Patient, 57 years, there has been a diagnosis of cirrhosis of the liver alcoholic etiology, asthma, portal hypertension stage III. Complications: bleeding from esophageal varices week ago, ascites, hepatic encephalopathy III degree.

At admission the patient is lethargic, apathetic, flapping tremor. History repeated gastrointestinal bleeding. There are personality changes, which include increased sociability on the background of irritability. Detected constructive apraxia, there has been a violation of the outlines of letters. It slowed down, solid, lethargically, hyperreactive reflexes, convulsions.

Identify elaut the ammonia level in the blood serum and the test is carried out the communication test numbers before and after treatment.

The patient is prescribed a diet with animal protein 0.3 g/kg/day for 10 days and then increase to 0.8 g/kg/day for 1 month, spend intravenous 5% glucose solution at a dose of 500 ml within 1 week, receiving lactulose dose of 90 ml, divided into 3 doses, for 4 weeks, taking probiotics - 30 minutes before meals for 2 weeks; then take L-ornithine-L-aspartate for 10 days at a dose of 40 g/day, divided into 3 doses, followed by a reception in a dose of 7 g 3 times daily for 10 days; prescribe probiotics (probfor 10 doses 3 times a day or Bifidumbacterin Forte 10 doses 3 times a day or Bifiform 2 capsules 2 times a day) for 30 min before meals for 2 weeks.

Before treatment, the ammonia level is 85 mmol/l and the test connection numbers 100 C. After 18 days of treatment the level of ammonia is reduced to 74 mmol/l, and the test connection number is reduced to 70 C. the results assess the patient's condition as satisfactory.

The patient was discharged in a state of clinical remission: decreased inhibition and symptoms of flapping tremor, uluchshilas social contacts, i.e. after treatment stabilized the psychosomatic state.

The patient was discharged in a state of clinical and laboratory remission. Follow-up observation for 1 year is e revealed the progression of symptoms of hepatic encephalopathy.

On the examination and treatment were 27 patients with hepatic encephalopathy in liver cirrhosis.

Assessed the status before and after treatment. Compared with the method of the prototype of the effectiveness of treatment of patients with hepatic encephalopathy on the background of cirrhosis of the liver is that it decreases the incidence of hepatic coma, increased protein tolerance, reverse the development of neurological and psychiatric manifestations of hepatic encephalopathy.

Sources of information

1. Handbook of children's neurology / edited by Lebedev BV M.: Medicine, 1995, S. 376.

2. Ivashkin V.T. diseases of the liver and biliary tract. A guide for physicians. M: Bulletin, 2002, 416 S.

1. The method of treatment of hepatic encephalopathy in liver cirrhosis, including reception of L-ornithine-L-aspartate, characterized in that the patient is prescribed a diet with animal protein 0.3-0.5 g/kg/day for 10 days, followed by its increase up to 0.8-1 g/kg/day for 1 month, spend intravenous 5%glucose solution at a dose of 400-500 ml in 1 week, receiving lactulose in doses of 60-90 ml, divided into 2-3 doses for 4 weeks, taking probiotics - 30 min before meals for 2 weeks, then take L-ornithine-L-aspartate for 10 days at a dose of 30-40 mg/day, divided into 2-3 doses, with subsequent receiving the dose of 5-7 g 3 times daily for 10 days.

2. The method of treatment of hepatic encephalopathy in liver cirrhosis according to claim 1, characterized in that as a probiotic use probfor 10 doses 3 times a day.

3. The method of treatment of hepatic encephalopathy in liver cirrhosis according to claim 1, characterized in that as a probiotic use Bifidumbacterin Forte 10 doses 3 times a day.

4. The method of treatment of hepatic encephalopathy in liver cirrhosis according to claim 1, characterized in that as a probiotic use Bifiform 2 capsules 2 times a day.



 

Same patents:

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to novel derivatives of pyrimidine of the general formula (I) that possess properties of antagonists to adenosine A2-receptors and can be effective in relieve, for example, of defecation. In compound of the general formula (I) each R1 and R2 represents hydrogen atom; R3 represents hydrogen atom, halogen atom, amino-group, cyano-group, alkyl group comprising 1-6 carbon atoms, alkoxy-group comprising 1-6 carbon atoms, alkenyloxy-group comprising 2-6 carbon atoms, phenyl group that can be substituted with halogen atom, pyridyl group, furyl group or thienyl group; R4 represents pyridyl that can be substituted with a substitute chosen from the group comprising: hydrogen atom, halogen atom, amino-group, mono- or dialkylamino-group, aminoalkylamino-group wherein each has in alkyl residue from 1 to 6 carbon atoms, alkyl group comprising from 1 to 6 carbon atoms that can be substituted with halogen atom, hydroxy-group, amino-group, mono- or dialkylamino-group, alkoxycarbonyl wherein each has in alkyl residue from 1 to 6 carbon atoms, alkoxy-group comprising in alkyl group from 1 to 6 carbon atoms substituted with phenyl or pyridyl, hydroxyalkoxy-group comprising in alkyl residue from 1 to 6 carbon atoms, hydroxycarbonyl, alkoxycarbonyl comprising from 1 to 6 carbon atoms in alkyl residue, alkenyl group comprising from 2 to 6 carbon atoms, alkynyl group comprising from 2 to 6 carbon atoms, piperidinyl group that can be substituted with hydroxyl group, or represents group of the formula (IV): R5 represents phenyl that can be substituted with halogen atom, pyridyl group, thienyl or furyl group.

EFFECT: valuable biological properties of derivatives.

16 cl, 2 tbl, 185 ex

FIELD: organic chemistry of heterocyclic compounds, medicine, pharmacy.

SUBSTANCE: invention relates to derivatives of pyrimidine of the general formula (I) and their pharmaceutically acceptable acid-additive salts possessing properties of neurokinin-1 (NK) receptors antagonists. In the general formula (I): R1 means lower alkyl, lower alkoxyl, pyridinyl, pyrimidinyl, phenyl, -S-lower alkyl, -S(O2)-lower alkyl, -N(R)-(CH2)n-N(R)2, -O-(CH)n-N(R)2, -N(R)2 or cyclic tertiary amine as a group of the formula: R1 means lower alkyl, lower alkoxyl, pyridinyl, pyrimidinyl, phenyl, -S-lower alkyl, -S(O2)-lower alkyl, -N(R)-(CH2)n-N(R)2, -O-(CH)-N(R)2, -N(R)2 or cyclic tertiary amine of the formula: that can comprise additional heteroatom chosen from atoms N, O or S, and wherein this group can be bound with pyrimidine ring by bridge -O-(CH2)n-; R2 means hydrogen atom, lower alkyl, lower alkoxyl, halogen atom or trifluoromethyl group; R3/R3' mean independently of one another hydrogen atom or lower alkyl; R4 means independently of one another halogen atom, trifluoromethyl group or lower alkoxyl; R means hydrogen atom or lower alkyl; R means independently of one another hydrogen atom or lower alkyl; X means -C(OH)N(R)- or -N(R)C(O)-; Y means -O-; n = 1, 2, 3 or 4; m means 0, 1 or 2. Also, invention relates to a pharmaceutical composition comprising one or some compounds by any claim among claims 1-19 and pharmaceutically acceptable excipients. Proposed compounds can be used in treatment, for example, inflammatory diseases, rheumatic arthritis, asthma, benign prostate hyperplasia, Alzheimer's diseases and others.

EFFECT: valuable medicinal properties of compounds and pharmaceutical composition.

21 cl, 1 tbl, 76 ex

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to using phenylethenyl- or phenylethynyl-derivatives as antagonists of glutamates receptors. Invention describes using compound of the general formula (I):

wherein each among R1, R2, R3, R4 and R5 means independently of one another hydrogen atom, (C1-C6)-alkyl, -(CH2)n-halogen, (C1-C6)-alkoxy-group, -(CH2)n-NRR', -(CH2)n-N(R)-C(O)-C1-C6)-alkyl, phenyl or pyrrolyl that can be unsubstituted or substituted with one or more (C1-C6)-alkyl; each among R, R' and R'' means independently of one another hydrogen atom or (C1-C6)-alkyl; A means -CH=CH- or C≡C; B means ,, , , or wherein R6 means hydrogen atom, (C1-C)-alkyl, -(CH2)n-C(O)OR, or halogen atom; R7 means hydrogen atom, (C1-C6)-alkyl, -(CH2)n-C(O)OR', halogen atom, nitro-group or oxodiazolyl group that can be unsubstituted or substituted with (C1-C6)-alkyl or cycloalkyl; R8 means hydrogen atom, (C1-C6)-alkyl, -(CH2)n-OH, -(CH2)n-C(O)OR'' or phenyl; R9 means (C1-C6)-alkyl; R10 and R11 mean hydrogen atom; R12 means -(CH2)n-N(R)-C(O)-(C1-C6)-alkyl; R13 means hydrogen atom; each R14, R15, R16 and R17 independently of one another means hydrogen atom or (C1-C6)-alkoxy-group; each R18, R19 and R20 independently of one another means hydrogen atom; R21 means hydrogen atom or (C1-C6)-alkyl; R22 means hydrogen atom, (C1-C6)-alkyl or (C1-C6)-alkyl comprising one or more substitutes chosen from groups hydroxy- or halogen atom; R23 means hydrogen atom, (C1-C6)-alkanoyl or nitro-group; each among R24, R25 and R26 independently of one another means hydrogen atom or (C1-C6)-alkyl; n = 0, 1, 2, 3, 4, 5 or 6; X means -O- or -S-; Y means -CH= or -N=, and its pharmaceutically acceptable salts used in preparing medicinal agents designates for treatment or prophylaxis of disorders mediated by mGluR5-receptors. Also, invention describes compounds of the formula (I-A), compound of the formula (I-B-1) given in the invention description, and a medicinal agent used in treatment or prophylaxis of disorders mediated by mGluR5-receptors.

EFFECT: valuable medicinal properties of compounds.

44 cl, 1 tbl, 44 ex

FIELD: medicine.

SUBSTANCE: method involves introducing recombinant human granulocytic colony-stimulating factor.

EFFECT: enhanced effectiveness of treatment; increased number of stem cells and their improved homing in lesion foci without polypragmasia effects.

5 tbl

FIELD: medicine.

SUBSTANCE: method involves introducing Hypoxen at a peroral dose of 0.5 g 40 min before premedication with Benzodiazepine series tranquilizer.

EFFECT: enhanced effectiveness in retaining psychic and motor functions after surgical intervention.

FIELD: medicine, veterinary science.

SUBSTANCE: invention relates to a method for improving the cognitive function in mammals and humans. Method involves administration in mammal needing in such treatment bis-[(2-hydroxyethyl)-N,N,N-trimethylaminium] succinate. This provides improving different cognitive functions in mammals being without the development of by-side effects and results to the improvement of the life quality and social adaptation in persons suffering with these disorders.

EFFECT: improved method for enhancing cognitive function.

2 tbl, 3 ex

FIELD: medicine, pharmacy.

SUBSTANCE: invention relates to a pharmaceutical composition possessing capacity to release the therapeutically effective dose of active substance rivastigmin and showing the time-controlled pattern. The pharmaceutical composition is designated for treatment of patients suffering with Alzheimer's diseases dementia from small to middle severity degree. Compositions show safety and time-controlled release pattern of active substance rivastigmin.

EFFECT: valuable medicinal and pharmaceutical properties of composition.

5 cl, 2 tbl, 7 ex

FIELD: medicine.

SUBSTANCE: invention relates to a method for treatment of diseases representing the result of cognitive disorders, in particular, Alzheimer's disease. Invention involves using (+)-enantiomer of fenserine - (+)-9-N-phenylcarbinoleseroline possessing the minimal anti-cholinesterase activity, or its pharmaceutically acceptable salt, for example, acid-additive salt, in particular, as an active component of a pharmaceutical composition. The dosed formulation of such composition comprises 20-500 mg of active component. The active component is given to a patient in the dose 0.5-10 mg/kg of body mass per a day. Invention provides achievement of clinic effect in said disorders in the absence of by-side toxic effect caused by anti-cholinesterase activity typical for agents that are used usually in these disorders.

EFFECT: improved method for treatment.

14 cl, 9 ex

FIELD: pharmacy.

SUBSTANCE: invention proposes a liquid pharmaceutical composition containing nicotine in any form for administration into the mouth cavity and alkalinized with a buffer and/or by regulation of pH value. Administration is carried out preferably by spraying and the most preferably by sublingual spraying. Also, invention relates to a method for preparing the indicated composition. Use of indicated composition in therapy, such as therapy for treatment of addiction to tobacco.

EFFECT: valuable pharmaceutical properties of composition.

51 cl, 11 ex

FIELD: organic chemistry, medicine, neurology, pharmacy.

SUBSTANCE: invention relates to derivatives of pyridazinone or triazinone represented by the following formula, their salts or their hydrates: wherein each among A1, A2 and A3 represents independently of one another phenyl group that can be optionally substituted with one or some groups chosen from the group including (1) hydroxy-group, (2) halogen atom, (3) nitrile group, (4) nitro-group, (5) (C1-C6)-alkyl group that can be substituted with at least one hydroxy-group, (6) (C1-C6)-alkoxy-group that can be substituted with at least one group chosen from the group including di-(C1-C6-alkyl)-alkylamino-group, hydroxy-group and pyridyl group, (7) (C1-C6)-alkylthio-group, (8) amino-group, (9) (C1-C6)-alkylsulfonyl group, (10) formyl group, (11) phenyl group, (12) trifluoromethylsulfonyloxy-group; pyridyl group that can be substituted with nitrile group or halogen atom or it can be N-oxidized; pyrimidyl group; pyrazinyl group; thienyl group; thiazolyl group; naphthyl group; benzodioxolyl group; Q represents oxygen atom (O); Z represents carbon atom (C) or nitrogen atom (N); each among X1, X2 and X3 represents independently of one another a simple bond or (C1-C6)-alkylene group optionally substituted with hydroxyl group; R1 represents hydrogen atom or (C1-C6)-alkyl group; R2 represents hydrogen atom; or R1 and R2 can be bound so that the group CR2-ZR1 forms a double carbon-carbon bond represented as C=C (under condition that when Z represents nitrogen atom (N) then R1 represents the unshared electron pair); R3 represents hydrogen atom or can be bound with any atom in A1 or A3 to form 5-6-membered heterocyclic ring comprising oxygen atom that is optionally substituted with hydroxyl group (under condition that (1) when Z represents nitrogen atom (N) then each among X1, X2 and X3 represents a simple bond; and each among A1, A2 and A3 represents phenyl group, (2) when Z represents nitrogen atom (N) then each among X1, X2 and X3 represents a simple bond; A1 represents o,p-dimethylphenyl group; A2 represents o-methylphenyl group, and A3 represents phenyl group, or (3) when Z represents nitrogen atom (N) then each among X1, X2 and X3 represents a simple bond; A1 represents o-methylphenyl group; A2 represents p-methoxyphenyl group, and A3 represents phenyl group, and at least one among R2 and R means the group distinct from hydrogen atom) with exception of some compounds determined in definite cases (1), (3)-(8), (10)-(16) and (19) given in claim 1 of the invention. Compounds of the formula (I) elicit inhibitory activity with respect to AMPA receptors and/or kainate receptors. Also, invention relates to a pharmaceutical composition used in treatment or prophylaxis of disease, such as epilepsy or demyelinization disease, such as cerebrospinal sclerosis wherein AMPA receptors take part, a method for treatment or prophylaxis of abovementioned diseases and using compound of the formula (I) for preparing a medicinal agent used in treatment or prophylaxis of abovementioned diseases.

EFFECT: valuable medicinal properties of compounds and pharmaceutical composition.

32 cl, 10 tbl, 129 ex

FIELD: medicine, hepatology, immunology.

SUBSTANCE: invention proposes using an opioid peptide DSLET of the formula: Tyr-D-Ser-Gly-Phe-Leu-Thr used for stimulation of reparative regeneration of liver and correction of immune reactivity under conditions of toxic hepatopathy. Opioid peptide DSLET is administrated by parenteral route (intaperitoneally) in the dose 50 mcg/kg of body mass in 0.1 ml of physiologically solution in course for 10 doses with break for 24 h between injections to experimental animal (rat) with toxic hepatopathy. The advantage of invention involves the possibility for using this peptide in toxic hepatopathy. Invention can be used for stimulation of regeneration of hepatocytes and correction of immune reactivity in experimental toxic hepatopathy.

EFFECT: valuable medicinal properties of agent.

2 tbl, 2 ex

FIELD: medicine, gastroentherology, in particular treatment of chronic viral hepatitis.

SUBSTANCE: claimed method includes daily administration intramuscularly of reaferone in dose of 3000000 Units per day in combination with administration perorally of liproxolre in dose of 2 g two times per day at 15-30 min before eating. Treatment course is 6 months.

EFFECT: method of increased effectiveness due to complex antiviral and antitoxic action.

3 ex

FIELD: medicine, in particular gastroentherology.

SUBSTANCE: claimed method includes complex administration of thiamine bromide, cyancobalamine, tiotriazoline, legalone and pancreatine. 1.0 ml of 5 % Thiamine bromide solution and 0.05 % cyancobalamine solution are administered intramuscularly every other day for 1 month, wherein for the initial ten days 2.5 % tiotriazoline solution in dose of 2 ml two times per day also are administered intramuscularly, and for the next 20 days tiotriazoline in pelleted form is administered in dose of 100 u three times per day. Moreover for whole month legalone in dose of 2 pellet per day and pancreatine in dose of 0.25 mg per day also are administered. Method of present invention makes it possible to recover of patient ability to work for 6-12 months.

EFFECT: improved method for treatment of alcoholic liver diseases.

2 ex, 4 tbl

FIELD: medicine, hepatology.

SUBSTANCE: invention relates to methods for treatment of patients suffering with liver diseases. Method involves administration of L-ornithine-L-aspartate by every day intravenous drop route for 7-10 days. Preliminary 10 g of this preparation are dissolved in 400 ml of low-molecular dextran. This method provides the effective treatment based on improved hemodynamics in liver.

EFFECT: improved method of treatment.

5 dwg, 3 ex

FIELD: organic chemistry.

SUBSTANCE: invention relates to new 2-amino-4-acetyl-7-bromo-8b-hydroxy-3a,8b-dihydroxytiazolo[5,4-b]indole of formula useful in liver protection from poisoning with carbon tetrachloride. Said compound has boiling point of 174-175°C (decomposition) and LD50 of 1950±180 mg/kg. Method for production of claimed compound also is disclosed.

EFFECT: new compound for liver protection from poisoning with carbon tetrachloride.

2 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: invention relates to using antagonist of EP4 receptors in preparing a medicinal preparation used in treatment of IL-6-mediated disease chosen from the group including alcoholic cirrhosis, amyloidosis, atherosclerosis, cardiac disease, sclerosis and responses in transplantation of organs.

EFFECT: valuable medicinal properties of ligands.

6 cl, 8 dwg, 380 ex

FIELD: pharmaceutical industry, in particular phospholipid-based pharmaceutical composition hawing hepatoprotective and metabolism normalizing activity in form of tablets, pellets, capsules, injection solutions, etc.

SUBSTANCE: claimed composition contains both plant and animal origin phospholipid, essential amino acid such as methionine and threonine, and filler at total phospholipid and amino acid content of 15-80 % in mass ratio of 2:1.

EFFECT: effective pharmaceutical composition having excellent hepatoprotective and lipid, protein, and carbohydrate metabolism normalizing activity.

12 cl, 26 tbl, 98 ex

FIELD: medicine.

SUBSTANCE: method involves administering hepatoprotector means and transplanting spinal marrow stem cells. The stem cells are selected from aspirated spinal marrow sample taken from the patient. The portion to be introduced is calculated so that the number of CD34-position cells is equal to 40-240x106 cells. Then the portion is divided into two halves of which the first one is intrahepatically introduced, and the second one is intravenously introduced.

EFFECT: enhanced effectiveness of treatment; reduced risk of hepatic cell insufficiency syndrome.

2 cl

FIELD: organic chemistry, chemical technology, medicine.

SUBSTANCE: invention relates to a new 2-amino-4-acetyl-7-bromo-8b-hydroxy-3a,8b-dihydrothiazolo[5,4-b]indole hydrobromide of the formula (1) that is able to protect body against hypoxia and liver against poisoning with carbon tetrachloride. The melting point of this compound is 266-267°C (with decomposition). The compound is synthesized from 1-acetyl-5-bromo-3-indolinone and elemental bromine in dioxane medium followed by addition of thiourea in isopropyl alcohol.

EFFECT: valuable medicinal properties of compound.

2 tbl, 1 ex

FIELD: medicine, in particular agent for treatment of hepatitis, toxoplasmosis, cytomegaloviral infection and influenza.

SUBSTANCE: claimed agent contains physiological saline for intravenous administration, comprising hydrogen peroxide, 0.2 % riboxine solution and decoction of liquorice roots in specific ratio.

EFFECT: non-toxic and effective agent for treatment of abovementioned diseases.

7 ex

FIELD: veterinary science.

SUBSTANCE: on proving the diagnosis one should introduce immune serum of animals-donors for sick calves till clinical recovery at the titers of hemagglutinins to IRT virus being 1:256, to PG-3 virus being 1:1280 and to VD-BC virus being 1:1024, and, additionally, it is necessary to apply a probiotic preparation lactobifadol at 32x108 microbial cells bifido- and 4x107 lactobacteria. The innovation increases the quantity of recovered animals, shortens the terms of therapy and the number of relapses.

EFFECT: higher efficiency of therapy.

2 ex, 3 tbl

Up!